Risk estimation of neuroblastoma patients using molecular markers.

Area of Science:

• Pediatric Oncology
• Molecular Genetics
• Cancer Research

Background:

• Neuroblastoma is a heterogeneous pediatric cancer with variable clinical courses.
• Current risk stratification relies on limited clinical and molecular markers, leading to misclassifications.
• Advances in genomic and gene expression profiling offer new insights into disease phenotypes.

Purpose of the Study:

• To review recent advances in molecular prognostic markers for neuroblastoma.
• To discuss the current and potential contribution of these markers to risk stratification systems.

Main Methods:

• Review of recent scientific literature on neuroblastoma molecular markers.
• Analysis of genomic alterations and gene expression profiles.
• Evaluation of DNA copy number changes and gene expression-based classifiers.

Main Results:

• Diverse clinical phenotypes of neuroblastoma correlate with specific cytogenetic aberrations and gene expression patterns.
• Molecular markers, including DNA copy number changes and gene expression profiles, show potential for more precise outcome prediction.
• Gene expression-based classifiers may outperform established prognostic variables.

Conclusions:

• Molecular prognostic markers are advancing the understanding and prediction of neuroblastoma patient outcomes.
• These markers hold significant potential for improving neuroblastoma risk stratification and guiding treatment decisions.